Marc Yeste-Velasco

Marc Yeste-Velasco

Auto-generated profile, based on publicly available information

Marc Yeste-Velasco

Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Autophagy
Verified
Journal Article
Closed access
PMPau Muñoz-Guardiola
Pau Muñoz-Guardiola
JCJosefina Casas
Josefina Casas
EMElisabet Megías-Roda
Elisabet Megías-Roda
SSSònia Solé
Sònia Solé
HPHéctor Perez-Montoyo
Héctor Perez-Montoyo
Jose M LizcanoJose M Lizcano
Jose M Lizcano
ABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced endometrial and squamous non-small cell lung carcinoma (NCT03366480). Previously, we showed that ABTL0812 induces TRIB3 pseudokinase expression, resulting in the inhibition of the AKT-MTORC1 axis and macroautophagy/autophagy-mediated cancer cell death. However, the precise molecular determinants involved in the cytotoxic autophagy caused by ABTL0812 remained unclear. Using a wide range of biochemical and lipidomic analyses, we demonstrated that ABTL0812 increases cellular long-chain dihydroceramides by impairing DEGS1 (delta 4-desaturase, sphingolipid 1) activity, which resulted in sustained ER stress and activated unfolded protein response (UPR) via ATF4-DDIT3-TRIB3 that ultimately promotes cytotoxic autophagy in cancer cells. Accordingly, pharmacological manipulation to increase cellular dihydroceramides or incubation with exogenous dihydroceramides resulted in ER stress, UPR and autophagy-mediated cancer cell death. Importantly, we have optimized a method to quantify mRNAs in blood samples from patients enrolled in the ongoing clinical trial, who showed significant increased DDIT3 and TRIB3 mRNAs. This is the first time that UPR markers are reported to change in human blood in response to any drug treatment, supporting their use as pharmacodynamic biomarkers for compounds that activate ER stress in humans. Finally, we found that MTORC1 inhibition and dihydroceramide accumulation synergized to induce autophagy and cytotoxicity, phenocopying the effect of ABTL0812. Given the fact that ABTL0812 is under clinical development, our findings support the hypothesis that manipulation of dihydroceramide levels might represents a new therapeutic strategy to target cancer. Abbreviations: 4-PBA: 4-phenylbutyrate; AKT: AKT serine/threonine kinase; ATG: autophagy related; ATF4: activating transcription factor 4; Cer: ceramide; DDIT3: DNA damage inducible transcript 3; DEGS1: delta 4-desaturase, sphingolipid 1; dhCer: dihydroceramide; EIF2A: eukaryotic translation initiation factor 2 alpha; EIF2AK3: eukaryotic translation initiation factor 2 alpha kinase 3; ER: endoplasmic reticulum; HSPA5: heat shock protein family A (Hsp70) member 5; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MEF: mouse embryonic fibroblast; MTORC1: mechanistic target of rapamycin kinase complex 1; NSCLC: non-small cell lung cancer; THC: Δ9-tetrahydrocannabinol; TRIB3: tribbles pseudokinase 3; XBP1: X-box binding protein 1; UPR: unfolded protein response.

1 July 2008 in Neuroscience
Verified
Journal Article
Closed access
Merce PallasMerce Pallas
Merce Pallas
JPJ.G. Pizarro
J.G. Pizarro
JGJ. Gutierrez-Cuesta
J. Gutierrez-Cuesta
NCN. Crespo-Biel
N. Crespo-Biel
DAD. Alvira
D. Alvira
Antoni CaminsAntoni Camins
Antoni Camins

1 June 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
ENElodie E. Noel
Elodie E. Noel
MYMarc Yeste-Velasco
Marc Yeste-Velasco
XMXueying Mao
Xueying Mao
JPJackie Perry
Jackie Perry
SKSakunthala C. Kudahetti
Sakunthala C. Kudahetti
Yong-jie LuYong-jie Lu
Yong-jie Lu

1 August 2015 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
MYMarc Yeste-Velasco
Marc Yeste-Velasco
MLMaurine E. Linder
Maurine E. Linder
Yong-jie LuYong-jie Lu
Yong-jie Lu

1 July 2007 in Neuroscience
Verified
Journal Article
Closed access
DAD. Alvira
D. Alvira
MYM. Yeste-Velasco
M. Yeste-Velasco
JFJaume Folch
Jaume Folch
EVE. Verdaguer
E. Verdaguer
ACA.M. Canudas
A.M. Canudas
Antoni CaminsAntoni Camins
Antoni Camins

19 October 2025 in Annals of Oncology
Verified
Journal Article
Open access
KFK Fizazi
K Fizazi
NCN W Clarke
N W Clarke
MSM De Santis
M De Santis
HUH Uemura
H Uemura
AFA P Fay
A P Fay
CGCAPItello-281 Study Group
CAPItello-281 Study Group
In metastatic hormone-sensitive prostate cancer (mHSPC), phosphatase and tensin homolog (PTEN) deficiency results in phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen receptor pathway inhibitors (ARPIs), resulting in worse outcomes. Dual inhibition of PI3K/AKT and AR pathways with capivasertib and abiraterone may delay progression and improve disease outcomes. In CAPItello-281 (NCT04493853), patients with PTEN-deficient mHSPC (diagnostic cut-off: ≥90% viable malignant cells with no specific cytoplasmic PTEN immunohistochemistry staining) received capivasertib or placebo (1 : 1) plus abiraterone, prednisone/prednisolone, and androgen deprivation therapy (ADT). The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS); overall survival (OS) was a key secondary endpoint. Post hoc exploratory subgroups at increasing PTEN cut-off thresholds were also assessed. 25.3% (1519/6003) of patients with valid tumor test results had PTEN-deficient tumors. In the randomized PTEN-deficient population, a statistically significant improvement in rPFS was observed with capivasertib plus abiraterone (n = 507, median 33.2 months) versus placebo plus abiraterone [n = 505, 25.7 months; hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.66-0.98, P = 0.034]. Post hoc rPFS analyses for loss of PTEN cut-offs of ≥95%, ≥99%, and 100% showed that the capivasertib plus abiraterone arm performed consistently across cut-offs, but the placebo plus abiraterone arm performed progressively worse as the cut-off for the degree of PTEN loss was increased, resulting in a numerically improved treatment effect. In the overall population studied, the HR for OS (26.4% maturity) was 0.90, 95% CI 0.71-1.15, P = 0.401. The most common adverse events (AEs) for capivasertib plus abiraterone were diarrhea (51.9%; 8.0% placebo plus abiraterone), hyperglycemia (38.0%; 12.9%), and rash (35.4%; 7.0%). Deaths associated with an AE were reported in 36 (7.2%) and 26 (5.2%) patients in the capivasertib plus abiraterone and placebo plus abiraterone arms, respectively. Capivasertib plus abiraterone improves rPFS versus placebo plus abiraterone in PTEN-deficient mHSPC, on a background of ADT, with a 7.5-month improvement in median rPFS. AE profile was consistent with that of the individual agents. Patients with PTEN-deficient mHSPC benefit from dual blockade of the PI3K/AKT and AR pathways with capivasertib plus abiraterone.